Back to results
US 2023/0414622 A1Published application
Pharmaceutical methotrexate composition
AssigneeLeopold MTX GmbH
InventorKarl Skriner
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions containing methotrexate or a pharmaceutically acceptable salt, hydrate, or derivative thereof, and a pharmaceutically active biopharmaceutical in a pharmaceutically acceptable solvent, are provided. Such compositions find medicinal use, inter alia, in the treatment of inflammatory autoimmune diseases such as rheumatoid arthritis.
Claims32
1:
- A pharmaceutical composition, comprising:
- methotrexate or a pharmaceutically acceptable salt, hydrate or derivative thereof,
- a pharmaceutically acceptable solvent, and
- at least one pharmaceutically active biopharmaceutical, which is at least partially dissolved in the solvent in combination with the methotrexate or the pharmaceutically acceptable salt, hydrate or derivative thereof.
1 more element
2:
- The pharmaceutical composition according to claim 1, wherein the methotrexate or the pharmaceutically acceptable salt, hydrate or derivative thereof is present in the solvent at a concentration of from 2.5 milligrams per milliliter to 100 milligrams per milliliter or at a concentration of from 5 milligrams per milliliter to 50 milligrams per milliliter.
3:
- The pharmaceutical composition according to claim 1, wherein the methotrexate or the pharmaceutically acceptable salt, hydrate or derivative thereof is present in the solvent at a concentration of from 5 milligrams per milliliter to 25 milligrams per milliliter or at a concentration of from 25 milligrams per milliliter to 50 milligrams per milliliter.
4:
- The pharmaceutical composition according to claim 1, wherein the at least one pharmaceutically active biopharmaceutical is present in the solvent at a concentration of from 1 milligram per milliliter to 150 milligrams per milliliter or at a concentration of from 5 milligrams per milliliter to 100 milligrams per milliliter.
5:
- The pharmaceutical composition according to claim 1, wherein the at least one pharmaceutically active biopharmaceutical is present in the solvent at a concentration of from 20 milligrams per milliliter to 50 milligrams per milliliter or at a concentration of from 25 milligrams per milliliter to 100 milligrams per milliliter.
6:
- The pharmaceutical composition according to claim 1, wherein the at least one pharmaceutically active biopharmaceutical is an immunosuppressive agent.
7:
- The pharmaceutical composition according to claim 1, wherein the at least one pharmaceutically active biopharmaceutical is a tumor necrosis factor-α inhibitor.
8:
- The pharmaceutical composition according to claim 1, wherein the at least one pharmaceutically active biopharmaceutical is a polypeptide or a protein having a binding domain for binding of a ligand or an antigen.
9:
- The pharmaceutical composition according to claim 8, wherein the ligand or antigen is selected from the group consisting of tumor necrosis factor-α, B lymphocyte antigen CD20, lymphocyte activation antigen CD80, cluster of differentiation 86 (CD86), and any combinations thereof.
10:
- The pharmaceutical composition according to claim 1, wherein the at least one pharmaceutically active biopharmaceutical is selected from the group consisting of adalimumab, etanercept, abatacept, infliximab, golimumab, rituximab, and any combinations thereof.
11:
- A method of treatment of an autoimmune inflammatory disease, comprising:
- administering an effective amount of the pharmaceutical composition according to claim 1 to a subject in need thereof.
12:
- The method according to claim 11, wherein that the treatment comprises a subcutaneous or intramuscular administration of the pharmaceutical composition performed by the subject itself.
13:
- The method according to claim 11, wherein the treatment comprises administration by a single-dose pre-filled syringe or by a pen-injector configured for multiple-dose administration of single doses.
14:
- The method according to claim 11, wherein the treatment comprises local administration of the pharmaceutical composition.
15:
- The method according to claim 11, wherein the treatment comprises intrafocal or intraarticular administration of the pharmaceutical composition.
16:
- The method according to claim 11, wherein the treatment comprises an oral administration of the pharmaceutical composition.
17:
- The method according to claim 11, wherein the methotrexate or the pharmaceutically acceptable salt, hydrate or derivative thereof is administered at a dose of from 2.5 milligrams to 25 milligrams per week.
18:
- The method according to claim 11, wherein the at least one pharmaceutically active biopharmaceutical is administered at a dose of from 5 mg to 50 mg per week.
19:
- The method according to claim 11, wherein the autoimmune inflammatory disease is selected from the group consisting of rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, systemic lupus erythematosus, systemic sclerosis, multiple sclerosis, Crohn's disease, ankylosing spondylitis, ulcerative colitis, polymyalgia rheumatica, vasculitis, and any combinations thereof.
20:
- The method according to claim 11, wherein the inflammatory disease is rheumatoid arthritis.
21:
- An injection device for subcutaneous or intramuscular administration of a medicament, wherein the injection device comprises a fluid reservoir containing the pharmaceutical composition according to claim 1.
22:
- The injection device according to claim 21, wherein the injection device is a pre-filled syringe containing a single dose of the pharmaceutical composition.
23:
- The injection device according to claim 21, wherein the injection device is a pen injector configured for delivering a plurality of single doses of the pharmaceutical composition.
24:
- The injection device according to claim 22, wherein the single dose comprises 2.5 milligrams to 25 milligrams or 5 milligrams to 50 milligrams of the methotrexate or the pharmaceutically acceptable salt, hydrate or derivative thereof, and/or 5 milligrams to 50 milligrams of the at least one pharmaceutically active biopharmaceutical.
25:
- A cartridge for a pen injector, wherein the cartridge comprises the pharmaceutical composition according to claim 1.
26:
- A sterile and/or sealed drug container, selected from the group consisting of a piercing vial, a vial, an infusion bag, a glass ampoule and a cartridge, wherein the drug container contains the pharmaceutical composition according to claim 1.
27:
- A drug-loaded nanoparticle or microparticle, wherein the nanoparticle or microparticle comprises the pharmaceutical composition according to claim 1.
28:
- A method for providing the injection device according to claim 21, the method comprising:
- filling the injection device with the pharmaceutical composition according to claim 1.
29:
- A method of preparing the pharmaceutical composition according to claim 1, comprising:
- providing methotrexate or a pharmaceutically acceptable salt, hydrate or derivative thereof,
- providing at least one pharmaceutically active biopharmaceutical, and
- at least partially dissolving the methotrexate or the pharmaceutically acceptable salt, hydrate or derivative thereof together with the at least one pharmaceutically active biopharmaceutical in a pharmaceutically acceptable solvent.
1 more element
30:
- A method for treating an inflammatory autoimmune disease of a patient with a drug combination comprising
- methotrexate or a pharmaceutically acceptable salt, hydrate or derivative thereof, and
- a pharmaceutically active biopharmaceutical,
- the method comprising:
- administering the methotrexate or the pharmaceutically acceptable salt, hydrate or derivative thereof with a first injection, and
- administering the pharmaceutically active biopharmaceutical with a second injection different from the first injection, intrafocally into an inflamed tissue or intraarticularly into an inflamed joint, wherein administration is performed such that within the tissue or joint the pharmaceutically active biopharmaceutical is contacted with the methotrexate or the pharmaceutically acceptable salt, hydrate or derivative thereof, to yield the drug combination.
3 more elements
31:
- The method according to claim 30, wherein the first and second injections are administered less than one hour apart in time.
32:
- A kit for the treatment of an inflammatory autoimmune disease of a subject with the method according to claim 30, wherein the kit comprises:
- a first injection device having a fluid reservoir containing the methotrexate or the pharmaceutically acceptable salt, hydrate or derivative thereof, and
- a second injection device separate from the first injection device, having a fluid reservoir containing the pharmaceutically active biopharmaceutical.